SubHero Banner

Pertzye® (pancrelipase) – Expanded indication and new formulation

October 11, 2016 – Digestive Care and Chiesi USA announced the FDA approval of a new infant-specific formulation and strength of Pertzye (pancrelipase), as a 4,000 lipase units delayed-release capsule, which expands the use of Pertzye to infants up to 12 months of age. 

Download PDF